Harry J. Leonhardt
Overview
Harry J. Leonhardt received an average of $1M in total compensation, including $422K in salary, at Poseida Therapeutics between 2021 and 2022. Harry Leonhardt also received an average of $2M at Halozyme Therapeutics from 2015 to 2019 and an average of $630K at Senomyx between 2006 and 2007.
- 2022
- 2021
- 2019
- 2018
- 2017
- 2016
- 2015
- 2007
- 2006
Poseida TherapeuticsGeneral Counsel, Chief Compliance Officer and Corporate Secretary
Poseida TherapeuticsGeneral Counsel, Chief Compliance Officer and Corporate Secretary
Halozyme TherapeuticsFormer Senior Vice President, General Counsel
Halozyme TherapeuticsSenior Vice President, General Counsel
Halozyme TherapeuticsSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Halozyme TherapeuticsSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Halozyme TherapeuticsSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
SenomyxSenior Vice President, General Counsel and Corporate Secretary
SenomyxSenior Vice President, General Counsel and Corporate Secretary
Source: SEC filings on April 26, 2023, March 20, 2020, March 22, 2019, March 22, 2018, March 24, 2017, and April 25, 2008.
Related executives
We found 34 more executives who work or worked at Poseida Therapeutics, Halozyme Therapeutics, andSenomyx.
Mark Gergen
Poseida Therapeutics
Chief Executive Officer
Kristin Yarema
Poseida Therapeutics
President, Cell Therapy
Brent Warner
Poseida Therapeutics
President, Gene Therapy
Eric Ostertag
Poseida Therapeutics
Chief Executive Officer
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
Masaru Matsuda
Halozyme Therapeutics
General Counsel
Michael LaBarre
Halozyme Therapeutics
Senior Vice President, Chief Technical Officer
Elaine Sun
Halozyme Therapeutics
Chief Financial Officer
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019